Galecto (GLTO) News Today → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free GLTO Stock Alerts $0.62 -0.01 (-1.58%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11, 2024 | americanbankingnews.comGalecto (NASDAQ:GLTO) Stock Price Down 2.9%May 3, 2024 | investorplace.comGLTO Stock Earnings: Galecto Beats EPS for Q1 2024May 1, 2024 | globenewswire.comGalecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with PembrolizumabApril 22, 2024 | theglobeandmail.com6 Stocks Positioned to Soar as Investors Focus on MASHMarch 15, 2024 | msn.comGLTO Stock Earnings: Galecto Beats EPS for Q4 2023February 16, 2024 | thestreet.comGalecto Inc.February 14, 2024 | finance.yahoo.comGalecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?January 9, 2024 | finance.yahoo.comWhat Makes Galecto, Inc. (GLTO) a New Strong Buy StockDecember 23, 2023 | finanznachrichten.deGalecto, Inc.: Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with MyelofibrosisDecember 22, 2023 | msn.comNike, AAR And 3 Stocks To Watch Heading Into FridayDecember 21, 2023 | finance.yahoo.comTopline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with MyelofibrosisOctober 23, 2023 | finance.yahoo.comGalecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 TrialOctober 5, 2023 | msn.comGalecto (GLTO) Price Target Increased by 13.16% to 5.48October 2, 2023 | finanznachrichten.deGalecto, Inc.: Galecto Announces Plans to Explore Strategic AlternativesSeptember 30, 2023 | msn.comHC Wainwright & Co. Downgrades Galecto (GLTO)September 27, 2023 | bizjournals.comWeeks after dropping lung disease drug, Galecto lays off most of staff, explores saleSeptember 26, 2023 | finance.yahoo.comGalecto Announces Plans to Explore Strategic AlternativesSeptember 14, 2023 | msn.comGalecto Biotech Collapse: Opportunity For Galectin TherapeuticsAugust 31, 2023 | finance.yahoo.comGalecto to Present at Investor Conferences in SeptemberAugust 22, 2023 | msn.comHC Wainwright & Co. Maintains Galecto (GLTO) Buy RecommendationAugust 21, 2023 | markets.businessinsider.comExpert Ratings for GalectoAugust 17, 2023 | finance.yahoo.comBiotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & MoreAugust 16, 2023 | marketwatch.comGalecto Ends Development of Lead Candidate After IPF Study Failure >GLTOAugust 16, 2023 | finance.yahoo.comGalecto (GLTO) Down 71% as Lung Disease Candidate FailsAugust 15, 2023 | msn.comSVB Leerink Downgrades Galecto (GLTO)August 15, 2023 | bizjournals.comGalecto shares plummet after biotech drops lung disease drugAugust 15, 2023 | msn.comWhy Is Galecto Stock Plummeting Today?August 15, 2023 | seekingalpha.comGalecto to drop lung disease drug after Phase 2 setbackAugust 15, 2023 | reuters.comGalecto to discontinue development of lung disease treatmentAugust 15, 2023 | markets.businessinsider.comGalecto: Phase 2b Trial Of GB0139 In Idiopathic Pulmonary Fibrosis Fail To Meet Main Goal;stock DownAugust 15, 2023 | msn.comGalecto shares drop 65% as biotech halts development of lung-disease treatmentAugust 15, 2023 | marketwatch.comGalecto Shares Sink to New Lows After Lead Drug Candidate Scrapped >GLTOAugust 15, 2023 | finance.yahoo.comGalecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary FibrosisAugust 15, 2023 | marketbeat.comTrading was temporarily halted for "GLTO" at 09:08 AM with a stated reason of "LULD pause."August 15, 2023 | marketbeat.comTrading was temporarily halted for "GLTO" at 07:08 AM with a stated reason of "News pending."August 3, 2023 | benzinga.comGalecto 10% Owner Sold $628K In Company StockAugust 1, 2023 | finanznachrichten.deGalecto, Inc.: Galecto Reports Second Quarter Operating and Financial ResultsAugust 1, 2023 | markets.businessinsider.comGalecto (GLTO) Receives a Buy from H.C. WainwrightAugust 1, 2023 | msn.comOppenheimer Reiterates Galecto (GLTO) Outperform RecommendationJuly 28, 2023 | finance.yahoo.comORBIMED ADVISORS LLC Reduces Stake in Galecto IncJuly 28, 2023 | benzinga.com10% Owner At This Health Care Company Sells $114K of StockJuly 19, 2023 | 247wallst.comOrbimed Advisors Now Owns 9.6% of GalectoJuly 18, 2023 | benzinga.comGalecto Recent Insider ActivityJuly 8, 2023 | morningstar.comGalecto Inc Ordinary SharesJuly 6, 2023 | msn.comGalecto (GLTO) Price Target Increased by 9.09% to 12.24June 20, 2023 | msn.comOppenheimer Initiates Coverage of Galecto (GLTO) with Outperform RecommendationJune 20, 2023 | seekingalpha.comGalecto to join Russell Microcap IndexJune 20, 2023 | msn.comGalecto an outperform at Oppenheimer on fibrosis assets catalystsJune 20, 2023 | finance.yahoo.comGalecto Set to Join Russell Microcap® IndexJune 20, 2023 | markets.businessinsider.comGalecto (GLTO) Initiated with a Buy at Oppenheimer Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (Ad)Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it. Click on Adam's shiny forehead for more details. GLTO Media Mentions By Week GLTO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLTO News Sentiment▼0.000.49▲Average Medical News Sentiment GLTO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLTO Articles This Week▼01▲GLTO Articles Average Week Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aytu BioPharma News Today Sol-Gel Technologies News Today VBI Vaccines News Today Indaptus Therapeutics News Today Cocrystal Pharma News Today GlycoMimetics News Today Minerva Neurosciences News Today Talphera News Today KALA BIO News Today NeuroBo Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLTO) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaWhat’s Really Next for America…Porter & Company[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
